EUVIMEDEUVIMED entdecken
Crossref

Multitargeted inhibition of key enzymes associated with diabetes and Alzheimer's disease by 1,3,4‐oxadiazole derivatives: Synthesis, in vitro screening, and computational studies

Bibi Fatima, Faiza Saleem, Uzma Salar, Sridevi Chigurupati, Shatha G Felemban, Zaheer Ul-Haq, Syeda S Tariq, Suliman A Almahmoud, Muhammad Taha, Syed T A Shah, Khalid M Khan iD

Archiv der Pharmazie · 2023

DOI: 10.1002/ardp.202300384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Bibi Fatima und 10 weiteren Autor:innen. Beteiligte Einrichtung: H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. Hauptthemen laut MEDLINE: Alzheimer Disease, Diabetes Mellitus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Sindh Higher Education Commission (SHEC), Pakistan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A library of 22 derivatives of 1,3,4‐oxadiazole‐2‐thiol was synthesized, structurally characterized, and assessed for its potential to inhibit α‐amylase, α‐glucosidase, acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and antioxidant activities. Most of the tested compounds demonstrated good to moderate inhibition potential; however, their activity was lower than that of the standard acarbose. Significantly, compound 3f exhibited the highest inhibition potential against α‐glucosidase and α‐amylase enzymes, with IC 50 values of 18.52 ± 0.09 and 20.25 ± 1.05 µM, respectively, in comparison to the standard acarbose (12.29 ± 0.26; 15.98 ± 0.14 µM). Compounds also demonstrated varying degrees of inhibitory potential against AChE (IC 50 = 9.25 ± 0.19 to 36.15 ± 0.12 µM) and BChE (IC 50 = 10.06 ± 0.43 to 35.13 ± 0.12 µM) enzymes compared to the standard donepezil (IC 50 = 2.01 ± 0.12; 3.12 ± 0.06 µM), as well as DPPH (IC 50 = 20.98 ± 0.06 to 52.83 ± 0.12 µM) and ABTS radical scavenging activities (IC 50 = 22.29 ± 0.18 to 47.98 ± 0.03 µM) in comparison to the standard ascorbic acid (IC 50 = 18.12 ± 0.15; 19.19 ± 0.72). The kinetic investigations have demonstrated that the compounds exhibit competitive‐type inhibition for α‐amylase, noncompetitive‐type inhibition for α‐glucosidase and AChE, and mixed‐type inhibition for BChE. Additionally, a molecular docking study was performed on all synthetic oxadiazoles to explore the interaction details of these compounds with the active sites of the enzymes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDiabetes MellitusHumansButyrylcholinesteraseAcetylcholinesterasealpha-GlucosidasesAcarboseMolecular Docking SimulationStructure-Activity RelationshipOxadiazolesalpha-Amylases

Stichwörter der Autor:innen

1,3,4-OxadiazoleAChE inhibitorBChE inhibitorα-amylase inhibitorα-glucosidase inhibitor

Substanzen

ButyrylcholinesteraseAcetylcholinesterase1,3,4-oxadiazolealpha-GlucosidasesAcarboseOxadiazolesalpha-Amylases

Autor:innen und Institutionen

  • H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
  • Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
  • Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia.
  • Department of Medical Laboratory Science, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia.
  • Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Department of Education, Sukkur IBA University, Sukkur, Pakistan.

ORCID-Profile: Khalid M Khan

Förderung

  • Sindh Higher Education Commission (SHEC), Pakistan

Zitieren

APA

Fatima, B., Saleem, F., Salar, U., Chigurupati, S., Felemban, S. G., Ul-Haq, Z., Tariq, S. S., Almahmoud, S. A., Taha, M., Shah, S. T. A., & Khan, K. M. (2023). Multitargeted inhibition of key enzymes associated with diabetes and Alzheimer's disease by 1,3,4‐oxadiazole derivatives: Synthesis, in vitro screening, and computational studies. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300384

Vancouver

Fatima B, Saleem F, Salar U, Chigurupati S, Felemban SG, Ul-Haq Z, et al. Multitargeted inhibition of key enzymes associated with diabetes and Alzheimer's disease by 1,3,4‐oxadiazole derivatives: Synthesis, in vitro screening, and computational studies. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300384

BibTeX
@article{Fatima2023,
  author = {Fatima, Bibi and Saleem, Faiza and Salar, Uzma and Chigurupati, Sridevi and Felemban, Shatha G and Ul-Haq, Zaheer and Tariq, Syeda S and Almahmoud, Suliman A and Taha, Muhammad and Shah, Syed T A and Khan, Khalid M},
  title = {Multitargeted inhibition of key enzymes associated with diabetes and Alzheimer's disease by 1,3,4‐oxadiazole derivatives: Synthesis, in vitro screening, and computational studies},
  journal = {Archiv der Pharmazie},
  year = {2023},
  doi = {10.1002/ardp.202300384}
}
Kostenlos starten →